Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-cash Items (2016 - 2025)

Altimmune (ALT) has disclosed Non-cash Items for 10 consecutive years, with $4.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items rose 28.91% to $4.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.5 million, a 28.91% increase, with the full-year FY2024 number at $5.8 million, down 65.49% from a year prior.
  • Non-cash Items was $4.5 million for Q3 2025 at Altimmune, up from $1.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $25.7 million in Q4 2022 to a low of $3642.0 in Q2 2022.
  • A 5-year average of $6.6 million and a median of $3.3 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: plummeted 99.98% in 2022, then surged 56168.29% in 2023.
  • Altimmune's Non-cash Items stood at $8.5 million in 2021, then soared by 204.07% to $25.7 million in 2022, then crashed by 34.23% to $16.9 million in 2023, then plummeted by 65.49% to $5.8 million in 2024, then fell by 22.89% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Non-cash Items are $4.5 million (Q3 2025), $1.1 million (Q2 2025), and $2.5 million (Q1 2025).